255 related articles for article (PubMed ID: 8462179)
1. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
6. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
7. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia.
Bercovich D; Friedlander Y; Korem S; Houminer A; Hoffman A; Kleinberg L; Shochat C; Leitersdorf E; Meiner V
Atherosclerosis; 2006 Mar; 185(1):97-107. PubMed ID: 16002074
[TBL] [Abstract][Full Text] [Related]
8. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
Dallongeville J; Fruchart JC; Pfister P; Bard JM
J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
[TBL] [Abstract][Full Text] [Related]
9. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
[TBL] [Abstract][Full Text] [Related]
11. Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia.
Leitersdorf E
Drugs; 1994; 47 Suppl 2():54-8. PubMed ID: 7517834
[TBL] [Abstract][Full Text] [Related]
12. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
13. Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population.
Assouline L; Levy E; Feoli-Fonseca JC; Godbout C; Lambert M
Pediatrics; 1995 Aug; 96(2 Pt 1):239-46. PubMed ID: 7630677
[TBL] [Abstract][Full Text] [Related]
14. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
15. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
Couture P; Brun LD; Szots F; Lelièvre M; Gaudet D; Després JP; Simard J; Lupien PJ; Gagné C
Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):1007-12. PubMed ID: 9633944
[TBL] [Abstract][Full Text] [Related]
16. Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia.
Sposito AC; Gonbert S; Bruckert E; Atassi M; Beucler I; Amsellem S; Khallouf O; Benlian P; Turpin G
Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):2078-82. PubMed ID: 14512370
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia.
Raungaard B; Brorholt-Petersen JU; Jensen HK; Faergeman O
J Clin Pharmacol; 2000 Apr; 40(4):421-9. PubMed ID: 10761170
[TBL] [Abstract][Full Text] [Related]
19. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Leitersdorf E; Muratti EN; Eliav O; Peters TK
Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
